uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Rhea-AI Summary

uniQure (NASDAQ:QURE) has successfully closed its upsized public offering, raising approximately $345 million in gross proceeds. The offering included 6,736,841 ordinary shares at $47.50 per share, including 947,368 additional shares from the underwriters' fully exercised option. Additionally, the company issued pre-funded warrants for 526,316 ordinary shares to certain investors.

The proceeds will fund commercialization readiness activities, potential commercial launch of AMT-130, development of clinical product candidates, business development initiatives, and general corporate purposes. The offering was managed by Leerink Partners, Stifel, Guggenheim Securities, and Van Lanschot Kempen as bookrunners, with H.C. Wainwright & Co. as lead manager.

Positive

• Successfully raised $345 million in gross proceeds through public offering
• Full exercise of underwriters' option to purchase additional shares indicates strong demand
• Funds secured for AMT-130 commercialization and clinical product development
• Strengthened balance sheet for business development initiatives

Negative

• Significant dilution for existing shareholders through issuance of over 6.7 million new shares
• Additional potential dilution from pre-funded warrants for 526,316 shares

Insights

Biotechnology Financial Analyst

uniQure's $345M capital raise significantly strengthens its financial position to support AMT-130 commercialization and pipeline advancement.

uniQure has successfully completed an upsized public offering that raised $345 million in gross proceeds through the sale of 6.74 million ordinary shares at $47.50 per share, plus pre-funded warrants for an additional 526,316 shares. The strong investor demand is evident from the underwriters' full exercise of their option to purchase additional shares (947,368 shares).

This capital raise materially strengthens uniQure's financial runway at a critical juncture. The company has specifically earmarked the proceeds for commercialization readiness activities and the potential commercial launch of AMT-130, their lead candidate. For a gene therapy company transitioning from clinical development to commercialization, this funding is vital as commercialization requires substantial investment in manufacturing infrastructure, sales force development, and market access activities.

The offering was managed by prestigious investment banks including Leerink Partners, Stifel, Guggenheim Securities, and Van Lanschot Kempen, indicating strong institutional support. The $47.50 share price represents a meaningful valuation benchmark for the company.

Beyond AMT-130 commercialization, uniQure plans to allocate funds to develop other clinical candidates and pursue business development initiatives—potentially signaling future licensing deals or acquisitions to expand their pipeline. This comprehensive financing strategy positions uniQure to execute across multiple strategic priorities without near-term capital constraints.

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering; and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $345 million. All securities in the offering were sold by uniQure.

uniQure intends to use the net proceeds from this offering to fund its commercialization readiness activities, the potential commercial launch of AMT-130 and related commercialization activities, the development of its other clinical product candidates, business development initiatives and research projects, and for general corporate purposes.

Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen acted as bookrunning managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

The offering was made pursuant to uniQure’s automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A final prospectus supplement and the accompanying prospectus relating to the offering has been filed with the SEC and may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at equitycapitalmarkets@vanlanschotkempen.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. 

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the intended use of net proceeds from the public offering and other statements identified by words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" and similar words or expressions.

Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: continued interest in our rare disease and gene therapy portfolio, the ability to develop our product candidates and technologies, regulatory developments, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on February 27, 2025, our Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2025 and July 29, 2025, the final prospectus supplement and the accompanying prospectus filed with the SEC, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts
For Investors:	For Media:
Chiara Russo	Tom Malone
Direct: 781-491-4371	Direct: 339-970-7758
Mobile: 617-306-9137	Mobile: 339-223-8541
c.russo@uniQure.com	t.malone@uniQure.com

FAQ

How much did uniQure (QURE) raise in its September 2025 public offering?

uniQure raised approximately $345 million in gross proceeds through the public offering of ordinary shares and pre-funded warrants.

What was the share price for uniQure's 2025 public offering?

uniQure priced its public offering at $47.50 per ordinary share.

How many shares did uniQure issue in its 2025 public offering?

uniQure issued 6,736,841 ordinary shares, including 947,368 shares from the fully exercised underwriters' option, plus pre-funded warrants for 526,316 shares.

How will uniQure use the proceeds from its 2025 public offering?

The proceeds will fund commercialization readiness activities, potential commercial launch of AMT-130, development of clinical product candidates, business development initiatives, and general corporate purposes.

Who were the underwriters for uniQure's 2025 public offering?

The offering was managed by Leerink Partners, Stifel, Guggenheim Securities, and Van Lanschot Kempen as bookrunners, with H.C. Wainwright & Co. as lead manager.